
Biotech Business - March 29, 2022
XNK Therapeutics raises 132 million SEK
The company has secured a private placement, to existing and new investors, led by Flerie Invest AB. The purpose of the issue is primarily to finance the company’s clinical development in multiple myeloma and other indications. The company’s lead investigational candidate drug is currently being evaluated in combination with Sanofi’s anti-CD38 antibody Sarclisa (Isatuximab) in […]

Acquisition - October 18, 2021
Flerie Invest leads acquisition of Cobra Biologics Matfors AB
Flerie Invest led a syndicate of investors in the 52 million USD acquisition of Charles River Laboratories Inc’s DNA and protein manufacturing subsidiary Cobra Biologics Matfors AB, including its 7,000 square-meter facility. The new entity will be called NorthX Biologics AB. “This acquisition is a major investment for us and fits well with Flerie’s strategy […]

Biotech Business - August 10, 2021
Toleranzia proposes directed share issue of 42 million SEK
The purpose of the share issue is to fund an enhanced clinical trial program that can shorten the development time and increase the commercial potential of the company’s drug candidate TOL2 – one of the company’s potentially curative treatments for severe autoimmune diseases. TOL2, is being developed to cure myasthenia gravis – an autoimmune nerve […]